This article was originally published on TipRanks.com bluebird bio, Inc.
bluebird bio, Inc. (BLUE), the gene therapy developer for severe genetic disorders and cancer, has reported weaker-than-expected results for the third quarter ended September 30, 2021.
Biotechnology company bluebird bio, Inc. (BLUE) announced that the Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) has approved the …
Bluebird Bio (BLUE) priced an offering of 9.09 million shares of its common stock at $55 each, the company said late on Monday.
The Biotech sector came back to life towards the end of 2019. The Nasdaq Biotechnology Index jumped up 20% between October and December, …
It’s a very rewarding trading day for investors in bluebird bio Inc (NASDAQ:BLUE) with shares up nearly 25%, making the stock Wall Street’s …
Canaccord’s John Newman sees 24% upside potential for BLUE shares.
A First Glance at This Hedge Fund Firm’s Strategic Q2 Moves in Biotech Sector
Here’s a Running Tab of Updates Which We Find Most Relevant
Ocular Therapeutix Inc Ocular Therapeutix Inc (NASDAQ:OCUL) investors seem to be concerned with the company’s future following the news that Antony Mattessich will succeed Dr. …